Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota
文献类型:期刊论文
作者 | Deng, Zhenzhen2,3,4; Wu, Ning2,3; Wang, Jing2,3![]() ![]() |
刊名 | INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
![]() |
出版日期 | 2021-12-15 |
卷号 | 193页码:789-798 |
关键词 | Fucoidan Metabolic syndrome Gut microbiota |
ISSN号 | 0141-8130 |
DOI | 10.1016/j.ijbiomac.2021.10.188 |
通讯作者 | Zhang, Quanbin(qbzhang@qdio.ac.cn) |
英文摘要 | Metabolic syndrome (MetS) is a pathological condition of a variety of metabolic abnormalities, which requires more urgent treatment and intervention. Fucoidan has been recommended as a supplement for health enhancement and disease management. Here, we first propose that the beneficial effect of low molecular weight fucoidan fraction LF2 in regulating metabolic syndrome induced by high-fat diet is similar to that of metformin, in terms of molecular mechanism and gut microbiota. The study found that LF2 significantly reduces fasting blood glucose, enhances insulin sensitivity and restores insulin homeostasis and lipid homeostasis. Moreover, LF2 reduced liver oxidative stress and inflammation, and improved hepatocyte steatosis. To decipher the mechanism behind this therapeutic effect, both the molecular mechanisms and gut microbiota were further analyzed. LF2 inhibited the activation of PI3K-Akt-mTOR axis and decreased the expression of SREBP-1c and PPAR gamma in liver. Interestingly, we found that LF2 and metformin have similar effects on gut microbiota, increasing the proportion of Verrucomicrobia and enriching the abundance of Akkermansia muciniphila, which is beneficial to host health. Collectively, our research clarifies the new application of fucoidan as a functional food for anti-MetS, and provides a new insight for fucoidan to exert systemic therapeutic effects from the perspective of molecular mechanism and gut microbiota. |
资助项目 | Major Scientific & Engineering Projects of Innovation in Shandong Province[2019JZZY010818] ; National Natural Science Fundation of China[42176137] ; STS project of the Chinese Academy of Sciences[KFJSTS-QYZD-195] ; Special Open Fund of Laboratory for Marine Biology and Biotechnology, Qingdao Pilot National Laboratory for Marine Science and Technology[OF2020NO02] ; K.C. Wong Education Foundation, CAS |
WOS研究方向 | Biochemistry & Molecular Biology ; Chemistry ; Polymer Science |
语种 | 英语 |
WOS记录号 | WOS:000729557700002 |
出版者 | ELSEVIER |
源URL | [http://ir.qdio.ac.cn/handle/337002/177497] ![]() |
专题 | 海洋研究所_实验海洋生物学重点实验室 |
通讯作者 | Zhang, Quanbin |
作者单位 | 1.Qingdao Brightmoon Seaweed Grp Co Ltd, State Key Lab Bioact Seaweed Subst, Qingdao, Peoples R China 2.Chinese Acad Sci, Inst Oceanol, CAS & Shandong Prov Key Lab Expt Marine Biol, Ctr Ocean Mega Sci, Qingdao 266071, Peoples R China 3.Qingdao Natl Lab Marine Sci & Tech, Lab Marine Biol & Biotechnol, Qingdao 266071, Peoples R China 4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
推荐引用方式 GB/T 7714 | Deng, Zhenzhen,Wu, Ning,Wang, Jing,et al. Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,2021,193:789-798. |
APA | Deng, Zhenzhen.,Wu, Ning.,Wang, Jing.,Geng, Lihua.,Yue, Yang.,...&Zhang, Quanbin.(2021).Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota.INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,193,789-798. |
MLA | Deng, Zhenzhen,et al."Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota".INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 193(2021):789-798. |
入库方式: OAI收割
来源:海洋研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。